Compare ENVB & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVB | XXII |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.3M |
| IPO Year | 2000 | 2011 |
| Metric | ENVB | XXII |
|---|---|---|
| Price | $2.03 | $3.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 251.9K | 28.1K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,914,675.00 | $25,832,530.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.67 |
| 52 Week High | $13.25 | $11.37 |
| Indicator | ENVB | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 40.77 |
| Support Level | $1.96 | $3.61 |
| Resistance Level | $4.29 | $6.86 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 30.60 | 6.64 |
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.